GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Globus Medical Inc (NYSE:GMED) » Definitions » Altman Z-Score

Globus Medical (Globus Medical) Altman Z-Score : 4.86 (As of Apr. 26, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Globus Medical Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 4.85 is strong.

Globus Medical has a Altman Z-Score of 4.86, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Globus Medical's Altman Z-Score or its related term are showing as below:

GMED' s Altman Z-Score Range Over the Past 10 Years
Min: 4.85   Med: 22.05   Max: 29.54
Current: 4.85

During the past 13 years, Globus Medical's highest Altman Z-Score was 29.54. The lowest was 4.85. And the median was 22.05.


Globus Medical Altman Z-Score Historical Data

The historical data trend for Globus Medical's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Globus Medical Altman Z-Score Chart

Globus Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.54 24.62 22.47 21.62 5.10

Globus Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.62 16.76 18.09 4.62 5.10

Competitive Comparison of Globus Medical's Altman Z-Score

For the Medical Devices subindustry, Globus Medical's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Globus Medical's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Globus Medical's Altman Z-Score falls into.



Globus Medical Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Globus Medical's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.2994+1.4*0.2236+3.3*0.033+0.6*6.2889+1.0*0.3084
=4.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $5,086 Mil.
Total Current Assets was $1,915 Mil.
Total Current Liabilities was $392 Mil.
Retained Earnings was $1,137 Mil.
Pre-Tax Income was 24.994 + 2.535 + 74.674 + 63.189 = $165 Mil.
Interest Expense was -2.581 + 0 + 0 + 0 = $-3 Mil.
Revenue was 616.534 + 383.639 + 291.615 + 276.688 = $1,568 Mil.
Market Cap (Today) was $6,843 Mil.
Total Liabilities was $1,088 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1915.374 - 392.347)/5086.083
=0.2994

X2=Retained Earnings/Total Assets
=1137.266/5086.083
=0.2236

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(165.392 - -2.581)/5086.083
=0.033

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=6843.074/1088.124
=6.2889

X5=Revenue/Total Assets
=1568.476/5086.083
=0.3084

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Globus Medical has a Altman Z-Score of 4.86 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Globus Medical  (NYSE:GMED) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Globus Medical Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Globus Medical's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Globus Medical (Globus Medical) Business Description

Traded in Other Exchanges
Address
2560 General Armistead Avenue, Audubon, PA, USA, 19403
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.
Executives
Leslie V Norwalk director C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Dan Wolterman director 3721 VALLEY CENTRE DR, SUITE 500, SAN DIEGO CA 92130
John A Deford director C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Dan Lemaitre director 2 MUSICK, IRVINE CA 92618
Keith W Pfeil officer: SVP, Chief Financial Officer GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Kelly Huller officer: SVP, General Counsel 2560 GENERAL ARMISTEAD AVENUE, AUDOBON PA 19403
David D Davidar director, officer: Vice President, Operations C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Daniel T Scavilla officer: Senior VP and CFO C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
David M Demski director, officer: President and COO C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert Andrew Douglas director 21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106
Stephen T Zarrilli director FIBERLINK COMMUNICATIONS CORP., 794 PENLLYN PIKE, BLUE BELL PA 19422
Anthony L Williams officer: Senior VP of Bus. Devel. & GC C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Steven Payne officer: Chief Accounting Officer C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
David C Paul director, 10 percent owner, officer: Chief Executive Officer C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403